CYP2A6 polymorphisms and risk for tobacco-related cancers.
Tobacco consumption is the main identifiable risk to cancer, contributing to the majority of tumors in upper aerodigestive tissues. The psychoactive compound responsible for tobacco addiction, nicotine and the potent carcinogens present at high concentrations either in cigarette mainstream smoke or in smokeless tobacco products, 4-(methylnitrosamino)-1-(3-pyridyl)-butanone (NNK) and N-nitrosonornicotine (NNN) can be metabolized by CYP2A6. CYP2A6 is expressed in many aerodigestive tissues with high interindividual variability. The CYP2A6 gene is highly polymorphic and CYP2A6 alleles coding for enzymes with altered expression or metabolic capacity produce alterations in nicotine metabolism in vivo and seem to influence smoking behavior. These polymorphisms may change the rate of NNK and NNN activation and, therefore, may influence cancer risk associated with tobacco consumption. However, to date only a few and inconclusive studies have addressed the risk that a given CYP2A6 polymorphism presents for the development of tobacco-related tumors. Most, but not all, show a reduced risk associated with alleles that result in decreased enzyme activity. The overlapping substrate specificity and tissue expression between CYP2A6 and the highly similar CYP2A13 may add to the conflicting results observed. The intricate regulation of CYP2A6 and the variation of structurally different chemical compounds capable of inhibiting CYP2A enzymes also add to the complexity. Finally, the interaction between polymorphisms of genes that code for CYP2A6, CYP2A13 and other potent carcinogen-metabolizing CYP enzymes may help to determine individuals that are at higher risk of developing tumors associated with tobacco consumption.
Rossini
Ana
A
Universidade do Estado do Rio de Janeiro, Instituto de Biologia Roberto Alcântara Gomes, Departamento de Bioquímica Brazil, Rio de Janeiro, Brazil.
de Almeida Simão
Tatiana
T
Albano
Rodolpho Mattos
RM
Pinto
Luis Felipe Ribeiro
LF
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D002273:Carcinogens / Q000493:pharmacokinetics / Q000633:toxicity*; D065637:Cytochrome P-450 CYP2A6; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics*; D009538:Nicotine / Q000493:pharmacokinetics / Q000633:toxicity; D011110:Polymorphism, Genetic; D012306:Risk; D013379:Substrate Specificity; D014026:Nicotiana
D002273:Carcinogens; D009538:Nicotine; D001189:Aryl Hydrocarbon Hydroxylases; C414206:CYP2A13 protein, human; C585710:CYP2A6 protein, human; D065637:Cytochrome P-450 CYP2A6